PMID- 19213061
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20131121
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 74 Suppl 1
DP  - 2009 Jul 1
TI  - Chronically anticoagulated patients who need surgery: can low-molecular-weight 
      heparins really be used to "bridge" patients instead of intravenous 
      unfractionated heparin?
PG  - S17-21
LID - 10.1002/ccd.22000 [doi]
AB  - Patients at high risk of arterial or venous thromboembolic events often receive 
      chronic treatment with long-term oral anticoagulants such as warfarin. However, 
      if these patients require an invasive procedure, they may require a temporary 
      interruption of their warfarin therapy to minimize their bleeding risk during the 
      procedure. As warfarin has a long half-life and an unpredictable pharmacokinetic 
      profile, short-acting parenteral anticoagulants, such as unfractionated heparin 
      (UFH) and low-molecular-weight heparin (LMWH), may be of benefit in protecting 
      the patient from thromboemboli while their warfarin dose is withheld. Such 
      "bridging therapy" has traditionally been provided in-hospital with intravenous 
      UFH; however, recent data have suggested that LMWH may be an effective 
      alternative, with potential cost-savings due to the ability to provide bridging 
      therapy in the outpatient setting.
CI  - (c) 2009 Wiley-Liss, Inc.
FAU - Jaff, Michael R
AU  - Jaff MR
AD  - Harvard Medical School, Massachusetts General Hospital Vascular Center, 55 Fruit 
      Street, Boston, MA 02114, USA. mjaff@partners.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects/economics
MH  - Blood Loss, Surgical/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Administration Schedule
MH  - Drug Costs
MH  - Heparin/*administration & dosage/adverse effects/economics
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects/economics
MH  - Hospital Costs
MH  - Humans
MH  - Length of Stay
MH  - Postoperative Hemorrhage/economics/*prevention & control
MH  - Risk Assessment
MH  - Stroke/prevention & control
MH  - Thromboembolism/prevention & control
MH  - Warfarin/*administration & dosage/adverse effects/economics
RF  - 19
EDAT- 2009/02/13 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/02/13 09:00
PHST- 2009/02/13 09:00 [entrez]
PHST- 2009/02/13 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
AID - 10.1002/ccd.22000 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S17-21. doi: 10.1002/ccd.22000.